CombiPhos Catalysts
How Non-Radioactive Isotope Technology Opens a New Dimension in Pharmaceutical Innovation

Over the past decade, artificial intelligence has reshaped the landscape of pharmaceutical research. From target prediction to generative molecule design, AI has permeated nearly every layer of drug discovery. Yet despite enormous investment and rapid algorithmic advances, the industry faces an uncomfortable truth: AI-driven drug discovery is not progressing as fast or as reliably as expected.

The bottleneck is not the models. The bottleneck is the data.

Specifically, the field lacks deep, structured, mechanistic datasets that allow AI to understand—not just approximate—how drugs behave.

The Missing Layer: Mechanistic Data Beneath Molecular Descriptors

Most AI systems are trained on molecular-level data: structural formulas, fingerprints, ADME/Tox profiles, potency values, SAR tables, and assay descriptions. This data layer captures the phenotypic surface of drug behavior—how a molecule acts as a whole—but omits the underlying atomic physics that govern reactivity, stability, metabolism, and degradation.

This creates four fundamental limitations:

1. Outcome without mechanism:
Molecular data shows what happened, not why.
2. Sparse structural variation:
Molecules in datasets differ at many positions simultaneously, preventing isolation of micro-level causal effects.
3. No atomic-scale resolution:
AI cannot learn how small, controlled atomic changes shape chemical behavior.
4. Poor extrapolation:
Models trained on macroscopic data often fail when predicting outside familiar chemical space.

To elevate AI from pattern recognition to mechanistic insight, the field needs a new, orthogonal data dimension: atomic-level data.

Atomic-Level Data: The Next Frontier in AI Drug Discovery

Atomic-scale perturbations—subtle changes in atomic mass, bond energies, and kinetic behavior—offer a powerful window into structure–function relationships. A single isotopic substitution can measurably shift:

• metabolic stability
• oxidative susceptibility
• enzymatic cleavage rates
• reaction kinetics
• protein-binding microdynamics
• conformational energy landscapes

Historically, however, this data has been almost impossible to obtain systematically. The limitations were both chemical and infrastructural:

• modifying isotopic atoms without changing molecular frameworks is synthetically challenging
• methods for isotope incorporation are scarce or unpublished
• each variant requires special synthesis through deuterium chemistry approaches
• no global dataset links controlled atomic changes to experimental outcomes

In short, the industry has lacked a scalable method for generating atomic-level datasets—until now.
Non-Radioactive Isotope Technology: The First Scalable Platform for Atomic-Level Data Generation

Non-radioactive isotopes, especially deuterium, provide an ideal probe for atomic-scale mechanistic studies. Deuterium differs from hydrogen in nuclear mass, allowing it to influence:

• C–H vs. C–D bond strength
• kinetic isotope effects
• metabolic transformation rates
• oxidative pathways
• molecular stability under enzymatic or chemical stress

Because deuterium substitution preserves the molecular skeleton, researchers can isolate the effect of altering one atom at a time—a level of precision unavailable through conventional medicinal chemistry.

Our company has spent more than a decade developing the most advanced non-radioactive isotope technologies in the world. This platform enables us to:

1. Generate atomic-level variants at virtually any molecular position
We can selectively replace hydrogen with deuterium across diverse pharmaceutical scaffolds.
2. Produce these variants reproducibly and at scale
We supply over 10,000 deuterated reagents to 1,000+ pharmaceutical companies in 22 countries, giving us deep insight into global R&D trends.
3. Measure atomic-level effects experimentally

Each isotopically modified variant can be evaluated for changes in:

• stability (half live)
• metabolism
• reactivity
• degradation pathways
• functional biological activity

4. Build the world’s first structured atomic-level dataset
Each controlled perturbation produces a clean, interpretable data point. Together, these data points form the foundation of the industry’s first atomic-level data layer.
This dataset fills the deepest gap in AI drug discovery and enables algorithms to learn not just correlations but mechanisms.

A New Paradigm: Integrating Atomic-Level and Molecular-Level Data

For the first time, AI platforms can combine two complementary data layers:

1. Molecular-level data
Describing how drugs behave as complete structures.
2. Atomic-level data
Revealing how microscopic, single-atom perturbations alter that behavior.
The integration of these datasets creates a multidimensional training foundation that AI has never previously had access to. This combined dataset enables:

• More accurate property prediction
• More reliable out-of-distribution extrapolation
• Mechanism-aware modeling instead of black-box correlation
• Better stability and metabolism prediction
• Higher-confidence generative design and optimization

This dual-layer structure pushes AI closer to the level of mechanistic reasoning historically achieved only through expert medicinal chemistry.

Building the Next Data Infrastructure for Pharmaceutical AI

As the field matures, it is becoming increasingly clear that algorithmic innovation—while important—is no longer the limiting factor. Instead, the greatest advances will come from richer, deeper, mechanistically grounded datasets.

Non-radioactive isotope technology provides the first scalable path to such data, enabling:

• systematic atomic-level perturbation
• precise mechanistic measurement
• controlled variable isolation
• robust dataset generation across drug classes

In effect, this technology constructs the missing substrate beneath all AI-driven drug discovery platforms: a structured atomic-level dataset layer.

Conclusion: A New Dimension in Drug Discovery

AI cannot fully understand drug behavior using only molecular-level data. To unlock predictive accuracy, generalization, and mechanistic insight, the field must integrate a new depth of information—data derived from the atomic scale, where the true determinants of stability, reactivity, and metabolism reside.

Non-radioactive isotope technology makes this possible for the first time, offering the dataset layer required to accelerate AI-driven innovation across the next decade.

Atomic-level data is not just an enhancement.

It is the missing foundation for the future of AI drug discovery.